Media headlines about Leap Therapeutics (NASDAQ:LPTX) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Leap Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave press coverage about the company an impact score of 45.4815087663215 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, January 9th.
Leap Therapeutics (NASDAQ LPTX) traded up $0.09 during mid-day trading on Friday, reaching $6.34. 27,422 shares of the company traded hands, compared to its average volume of 58,859. The firm has a market capitalization of $78.32 and a P/E ratio of -1.83. Leap Therapeutics has a 1-year low of $4.90 and a 1-year high of $10.10.
Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.11). equities analysts forecast that Leap Therapeutics will post -3.63 earnings per share for the current fiscal year.
In other Leap Therapeutics news, COO Augustine Lawlor purchased 1,057,769 shares of the company’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average cost of $6.09 per share, for a total transaction of $6,441,813.21. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 58.40% of the stock is currently owned by insiders.
About Leap Therapeutics
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.